Illustration showing repaglinide (yellow, white, blue and red spheres within pink structures) binding to ATP-dependent potassium channel (multicoloured globular/helical structures) on a lipid vesicle in a pancreatic beta cell. Repaglinide belongs to a class of drugs known as meglitinides which bind to this type of receptor in pancreatic beta cells, stimulating insulin release. Insulin, in turn, increases cellular glucose uptake, reducing blood sugar levels, making repaglinide a suitable treatment for type 2 diabetes.